A review by Baker et al. highlighted a rare contiguous deletion in chromosome 9p21.3 obliterating ~25 genes including CDKN2A, CDKN2B and MTAP in a melanoma-prone family with additional tumour spectrum (neural system tumours, leukaemia, chondrosarcoma, pontomedullary PNET and cervical cancer),25 supporting our findings that genetic alterations involving CDKN2A could potentially underlie hereditary predisposition to cancers beyond melanoma. This evidence concerns the gene CDKN2A and leukemia.